Paper Details

  1. Home
  2. Paper Details

Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.

Author: MarziniakMartin, MeuthSven

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes the clinical trial and follow-up data for interferon beta-1b, a disease-modifying therapy for multiple sclerosis (MS). The drug has been shown to be effective and safe over 21 years of follow-up data and is now one of seven first-line treatments for relapsing-remitting MS.
Paper Details　
Original Abstract of the Article :
Interferon (IFN) beta-1b was the first disease-modifying therapy to be approved for the treatment of multiple sclerosis (MS), and over 21 years of follow-up data demonstrate its efficacy and long-term safety profile. Following recent regulatory approvals in the USA and European Union, IFN beta-1b is...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177103/

データ提供：米国国立医学図書館（NLM）

Interferon Beta-1b: A Long-Standing Treatment for Multiple Sclerosis

Multiple sclerosis (MS) is a complex neurological disease with a wide range of symptoms. This research delves into the long-term efficacy and safety profile of interferon (IFN) beta-1b, one of the first disease-modifying therapies approved for MS. The study reviews extensive data from clinical trials and follow-up studies, highlighting the role of IFN beta-1b in managing relapsing-remitting MS.

IFN Beta-1b: A Proven Treatment for Relapsing-Remitting MS

The study confirms the efficacy of IFN beta-1b in reducing the frequency and severity of MS relapses. Over 21 years of data demonstrate its effectiveness in slowing disease progression. IFN beta-1b is now widely recognized as a first-line treatment option for relapsing-remitting MS and remains a valuable tool in managing the disease.

Making Informed Decisions About MS Treatment

This research provides valuable information for healthcare professionals and patients seeking treatment for MS. The study highlights the importance of understanding the long-term safety and efficacy of IFN beta-1b, as well as the various treatment options available for MS.

Dr. Camel's Conclusion

In the vast desert of MS research, IFN beta-1b has emerged as a reliable oasis, providing long-term relief and slowing the progression of the disease. The study's findings offer a valuable roadmap for navigating the challenges of MS, highlighting the importance of understanding treatment options and making informed decisions about care.

Date :
  1. Date Completed 2016-03-09
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

25182864

DOI: Digital Object Identifier

PMC4177103

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.